Minnesota is currently home to 2098 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
NCT06859294
Recruiting
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: Saint Paul Rheumatology, Eagan, Minnesota
Conditions: Rheumatoid Arthritis
Register for Updates
Melatonin Effects on Cardiovascular Disease Mechanisms in the Menopause Transition: A Randomized Clinical Trial
NCT06826755
Recruiting
The purpose of this research is to study the effects of 12 weeks of melatonin supplementation compared to placebo in women who are in the menopause transition (perimenopause) and have high blood pressure.
Gender:
FEMALE
Ages:
Between 40 years and 55 years
Trial Updated:
05/23/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Perimenopause, Hypertension
Register for Updates
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076
Recruiting
The primary purpose of the study is to assess how well amivantamab subcutaneous (SC) administration in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University Of Minnesota, Minneapolis, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/23/2025
Locations: Akero Clinical Study Site, Rochester, Minnesota
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)
NCT06489028
Recruiting
The aim of this clinical trial is to investigate the efficacy and safety of allo-APZ2-CVU, administered topically on therapy-resistant non-healing CVUs compared to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: RHEACELL Clinical Trial Site, Minneapolis, Minnesota
Conditions: Venous Leg Ulcer
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Research Site, Minneapolis, Minnesota
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738
Recruiting
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Clinical Trial Site, St Louis Park, Minnesota
Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Register for Updates
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT05734105
Recruiting
This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota
Conditions: GIST
Register for Updates
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
Recruiting
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.
Gender:
ALL
Ages:
All
Trial Updated:
05/23/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Register for Updates
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
NCT05134012
Recruiting
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Coronary Artery Disease
Register for Updates